PEMBROLIZUMAB, BNT327 20 mg ml, BNT327 50 mg ml clinical trials

ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%

This study is comparing a new medicine called Pumitamig with a standard treatment, Pembrolizumab, for a type of lung cancer. Researchers want to see if Pumitamig can stop cancer from growing for longer or help people live longer than current treatment.